Black Diamond Therapeutics, Inc. (BDTX)
NASDAQ: BDTX · Real-Time Price · USD
2.220
+0.030 (1.37%)
At close: Dec 20, 2024, 4:00 PM
2.260
+0.040 (1.80%)
After-hours: Dec 20, 2024, 5:48 PM EST
BDTX Employees
Black Diamond Therapeutics had 54 employees as of December 31, 2023. The number of employees decreased by 11 or -16.92% compared to the previous year.
Employees
54
Change (1Y)
-11
Growth (1Y)
-16.92%
Revenue / Employee
n/a
Profits / Employee
-$1,353,685
Market Cap
125.62M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 54 | -11 | -16.92% |
| Dec 31, 2022 | 65 | -21 | -24.42% |
| Dec 31, 2021 | 86 | 17 | 24.64% |
| Dec 31, 2020 | 69 | 37 | 115.63% |
| Dec 31, 2019 | 32 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Akoya Biosciences | 330 |
| Protalix BioTherapeutics | 208 |
| Enanta Pharmaceuticals | 145 |
| TriSalus Life Sciences | 112 |
| Tonix Pharmaceuticals Holding | 103 |
| InflaRx | 62 |
| Elutia | 54 |
| Atossa Therapeutics | 12 |
BDTX News
- 6 weeks ago - Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 7 weeks ago - Black Diamond Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Black Diamond: EGFRm NSCLC Targeting Continues With Q1 Of 2025 Data - Seeking Alpha
- 2 months ago - Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway - GlobeNewsWire
- 3 months ago - Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations - GlobeNewsWire
- 3 months ago - Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC - GlobeNewsWire
- 3 months ago - Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024 - GlobeNewsWire
- 4 months ago - Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire